Hepatitis B Virus Prevalence and Vaccine Response in HIV-infected Children and Adolescents on Combination Antiretroviral Therapy in Kigali, Rwanda

Objective: The aim of this study was to determine the prevalence of hepatitis B virus (HBV) infection in a cohort of HIV-infected Rwandan children and adolescents on combination antiretroviral therapy (cART), and the success rate of HBV vaccination in those children found to be HBV negative. Methods: HIV-infected children and adolescents (age 8–17 years) receiving cART with CD4 T-cells count ≥200 cells/mm3 and/or ≥15% and without prior HBV vaccination (by history, vaccination cards and clinic records) underwent serologic testing for past (negative HBV surface antigen [HBsAg] with positive antibody to HBV core antigen [cAb] and to HBsAg [anti-HBs]) or active HBV infection (positive HBsAg). Children with any positive HBV serologic tests were excluded from further vaccination; all others completed 3 HBV immunizations with 10 µg of ENGERIX-B. Anti-HBs titer was measured 4–6 weeks after the last immunization. Results: Of 88 children, 6 (7%) children had active HBV infection and 8 (9%) had past HBV infection. The median (interquartile range) age, CD4 T-cell count and cART duration were 12.3 (10.1–13.9) years, 626 (503 to 942) cells/mm3 and 1.9 (1.5–2.7) years, respectively. Seventeen children had detectable plasma HIV-1 RNA. Seventy-3 children completed 3 immunizations with median (interquartile range) postimmunization anti-HBs concentration of 151 mIU/mL (1.03–650). Overall, 52 children (71%, 95% confidence interval: 61–82) developed a protective anti-HBs response. HIV-1 RNA and CD4 T-cell count were independent predictors of a protective anti-HBs response. Protective anti-HBs response was achieved in 82% of children with undetectable HIV-1 RNA and 77% with CD4 T cells ≥350/mm3. Conclusions: The substantial HBV prevalence in this cohort suggests that HIV-infected Rwandan children should be screened for HBV before cART initiation. HIV viral suppression and CD4 T cells ≥350/mm3 favored the likelihood of a protective response after HBV vaccination.Key Words: Hepatitis B, HIV-infected children and adolescents, Rwanda.

[1]  D. Jamieson,et al.  HIV-HBV coinfection--a global challenge. , 2012, The New England journal of medicine.

[2]  A. Morcillo,et al.  Impaired Humoral Response to Vaccines among HIV-Exposed Uninfected Infants , 2011, Clinical and Vaccine Immunology.

[3]  B. Kapogiannis,et al.  Hepatitis B Vaccination in HIV-Infected Youth: A Randomized Trial of Three Regimens , 2011, Journal of acquired immune deficiency syndromes.

[4]  S. Pol,et al.  The impact of human immunodeficiency virus on viral hepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[5]  Helen M. Chun,et al.  American Journal of Epidemiology Original Contribution the Timing of Hepatitis B Virus (hbv) Immunization Relative to Human Immunodeficiency Virus (hiv) Diagnosis and the Risk of Hbv Infection following Hiv Diagnosis , 2022 .

[6]  V. Sharp,et al.  Predictors of loss of hepatitis B surface antigen in HIV-infected patients. , 2010, World journal of gastroenterology.

[7]  L. Camacho,et al.  High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. , 2010, Vaccine.

[8]  É. Ono,et al.  Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART. , 2010, Vaccine.

[9]  H. Abubakar,et al.  Study of hepatic functions and prevalence of hepatitis B surface antigenaemia in Nigerian children with human immunodeficiency virus infection. , 2010, Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria.

[10]  W. Borkowsky,et al.  Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. , 2009, The Journal of infectious diseases.

[11]  T. Dellit,et al.  Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations , 2009, International journal of STD & AIDS.

[12]  C. Thio.  Hepatitis B and human immunodeficiency virus coinfection , 2009, Hepatology.

[13]  J. Hübschen,et al.  Exceptional genetic variability of hepatitis B virus indicates that Rwanda is east of an emerging African genotype E/A1 divide , 2009, Journal of medical virology.

[14]  C. Mengoli,et al.  Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. , 2009, Vaccine.

[15]  R. Harrington,et al.  Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons , 2008, International journal of STD & AIDS.

[16]  A. De Luca,et al.  Serological response to hepatitis B virus vaccine in HIV‐infected children in Tanzania , 2008, HIV medicine.

[17]  S. Zeichner,et al.  Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. , 2008, The Journal of pediatrics.

[18]  C. Rouzioux,et al.  Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Giuliano,et al.  Seroprevalence of hepatitis B and C viruses among HIV‐infected pregnant women in Uganda and Rwanda , 2007, Journal of medical virology.

[20]  M. Matee,et al.  Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania , 2007, BMC public health.

[21]  L. Aurpibul,et al.  Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. , 2007, Vaccine.

[22]  J. Correas,et al.  Reversibility of Cirrhosis in HIV/HBV Coinfection , 2006, Antiviral therapy.

[23]  A. Duarte,et al.  Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects. , 2006, Vaccine.

[24]  J. Brok,et al.  Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis , 2006, BMJ : British Medical Journal.

[25]  R. Bruno,et al.  Natural history of chronic hepatitis B in co-infected patients. , 2006, Journal of hepatology.

[26]  W. Powderly,et al.  Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  L. Finelli,et al.  Epidemiology of Hepatitis B and Hepatitis B Virus Infection in United States Children , 2005, The Pediatric infectious disease journal.

[28]  A. Barone,et al.  Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. , 2005, Vaccine.

[29]  K. Luzuriaga,et al.  Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. , 2004, The Lancet. Infectious diseases.

[30]  T. Wright.  Clinical trial results and treatment resistance with lamivudine in hepatitis B. , 2004, Seminars in liver disease.

[31]  Lasheras Lozano Ml,et al.  Hepatitis B vaccination in children and adolescents , 1993 .

[32]  J. Rey Calero,et al.  [Hepatitis B vaccination in children and adolescents]. , 1993, Atencion primaria.

[33]  N. Principi,et al.  Impaired response to hepatitis B vaccine in HIV infected children. , 1992, Vaccine.

[34]  P. Grosheide,et al.  [Hepatitis B in children]. , 1990, Tijdschrift voor kindergeneeskunde.